For research use only. Not for therapeutic Use.
Potent inhibitor of mTOR signalling (IC50 value 10 – 15 nM in vitro and in vivo) with very high selectivity over other kinases, including PI3Ks. The selectivity profile of eCF309 is as good as or even better than that of any other selective mTOR inhibitor reported to date, making it a highly valuable probe for chemical biology and biomedicine.
Note: Produced by and sold in collaboration with University of Edinburgh
KEYWORDS: eCF309 | supplier | mTOR inhibitor | eCF-309 | CAS [2001571-40-8] | Phosphatidylinositol | mTOR | rapamycin | PI3K | cancer
| Catalog Number | I006269 |
| CAS Number | 2001571-40-8 |
| Molecular Formula | C18H21N7O3 |
| Purity | ≥95% |
| IUPAC Name | 5-[4-amino-1-(2,2-diethoxyethyl)pyrazolo[3,4-d]pyrimidin-3-yl]-1,3-benzoxazol-2-amine |
| InChI | InChI=1S/C18H21N7O3/c1-3-26-13(27-4-2)8-25-17-14(16(19)21-9-22-17)15(24-25)10-5-6-12-11(7-10)23-18(20)28-12/h5-7,9,13H,3-4,8H2,1-2H3,(H2,20,23)(H2,19,21,22) |
| SMILES | CCOC(CN1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N)OCC |
| Reference | C Fraser et al. eCF309: a potent, selective and cell-permeable mTOR inhibitor. Med. Chem. Commun., 2016,7, 471-477.
C Fraser et al. Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL. J Med Chem. 2016 May 26; 59(10): 4697–4710. |
